(Q35575008)

8 August 2017

1 reference

title

Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline (English)

1 reference

8 August 2017

sertraline hydrochloride

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

28 March 2024

author name string

Uriel Halbreich

1

1 reference

8 August 2017

Linda S. Kahn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14596660

28 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14656566.4.11.2065

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Expert Opinion on Pharmacotherapy

28 March 2024

published in

1 reference

8 August 2017

4

1 reference

8 August 2017

11

1 reference

8 August 2017

2065-2078

1 reference

Severity of premenstrual symptoms in a health maintenance organization population

8 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Premenstrual dysphoric disorder: is there an economic burden of illness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Biological, social, and behavioral factors associated with premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Premenstrual Affective Syndrome and Affective Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Premenstrual mood changes and maternal mental health in pregnancy and the postpartum period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

The pathophysiologic background for current treatments of premenstrual syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Fluoxetine in the treatment of premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Paroxetine as a treatment for premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Effect of clomipramine on premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Review of sertraline and its clinical applications in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

The Role of Metabolites of Antidepressants in the Treatment of Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Selective serotonin reuptake inhibitor discontinuation syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Review of sertraline in post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Sudden cardiac death with clozapine and sertraline combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

The effect of sertraline on methadone plasma levels in methadone-maintenance patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Management of major depression during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Birth outcomes after prenatal exposure to antidepressant medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

Pharmacologic treatment of depression during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

The premenstrual symptoms screening tool (PSST) for clinicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2065

A Follow-Up Study of Premenstrual Syndrome

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Prevalence, incidence and stability of premenstrual dysphoric disorder in the community

28 March 2024

3

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women

28 March 2024

5

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Late luteal phase dysphoric disorder in young women

28 March 2024

8

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Prevalene of perimenstrual symptoms

28 March 2024

11

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Premenstrual dysphoric disorders, anxiety, and depressions: vulnerability traits or comorbidity

28 March 2024

13

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Characteristics of women seeking treatment for premenstrual syndrome.

28 March 2024

17

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder

28 March 2024

18

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Fluoxetine in the treatment of premenstrual dysphoria

28 March 2024

29

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder

28 March 2024

31

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome

28 March 2024

35

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome

28 March 2024

36

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial.

28 March 2024

43

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Treatment of premenstrual dysphoria with alprazolam. A controlled study.

28 March 2024

46

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

The premenstrual syndrome. Effects of "medical ovariectomy"

28 March 2024

50

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.

28 March 2024

51

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study

28 March 2024

52

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome

28 March 2024

53

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Buserelin in premenstrual syndrome

28 March 2024

54

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo

28 March 2024

56

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes

28 March 2024

60

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome

28 March 2024

64

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Serotonin levels and platelet uptake during premenstrual tension

28 March 2024

65

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes

28 March 2024

67

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change

28 March 2024

68

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.

28 March 2024

77

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia

28 March 2024

78

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions

28 March 2024

84

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

A rating scale for depression

28 March 2024

85

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Assessment of social adjustment by patient self-report

28 March 2024

86

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Premenstrual changes: patterns and correlates of daily ratings

28 March 2024

88

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system

28 March 2024

92

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Newer antidepressants and the cytochrome P450 system

28 March 2024

94

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

28 March 2024

98

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Interaction of sertraline with clozapine

28 March 2024

102

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports

28 March 2024

103

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors

28 March 2024

105

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

Lamotrigine toxicity secondary to sertraline

28 March 2024

108

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2065

28 March 2024

Identifiers

1 reference

8 August 2017

1 reference